-
-
-
-
-
-
-
Nurix (NRIX) PT Raised to $33 at RBC Capital; 'I&I Opportunities Remain Underappreciated'
-
-
-
-
-
-
-
Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity'
-
-
-
-
-
-
-
RBC Capital on Nurix (NRIX): 'Execution in CLL Remains Key'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX)
-
-
-
-
-
-
-
NASDAQ: NRIX Nurix outlines 2026 goals for BTK degrader bexobrutideg
-
-
-
-
-
-
-
Nurix presents clinical data showing NX-1607 activates immune system
-
-
-
-
-
-
-
Nurix (NRIX) PT Lowered to $33 at Stifel
-
446,526 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

